Private Placement-Non-Brokered
MED BIOGENE INC. ("MBI")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: September 28, 2009
TSX Venture Tier 2 Company
TSX Venture Exchange has accepted for filing documentation with respect to
a Non-Brokered Private Placement announced April 22, 2009:
Number of Shares: 20,625,001 shares
Purchase Price: $0.08 per share
Warrants: 10,312,500 share purchase warrants to purchase
10,312,500 shares
Warrant Exercise Price: $0.10 for a two year period subject to an
accelerated exercise provision where if the
closing price of the Company's common shares is
greater than $0.30 for 20 consecutive trading
days, the Issuer may give notice to
warrantholders that the expiry date for exercise
of the warrants has been accelerated and that
the warrants will expire on the 20th business
day following the of such notice.
Number of Placees: 49 placees
Insider/Pro Group Participation:
Insider equals Y/
Name ProGroup equals P/ No. of Shares
Wayne McNeill P 2,500,000
E. Graeme May P 1,662,500
Erinn B. Broshko Y 843,488
Bertilvic Investments
(Bolder Investment
Partners Ltd.) P 500,000
David G. Matthews Y 16,513
Hayden Bergman Rooney,
Professional Y 625,000
Corporation (Kevin K.
Rooney/Michael
Hayden/Peter Bergman)
Kevin K. Rooney Y 1,315,307
Finder's Fee: Fraser Mackenzie ($5,600 in cash and 70,000
options), Emerging Equities Inc. ($56 in cash
and 700 options), CIBC World Markets ($14,000 in
cash and 175,00 options), Raymond James Ltd.
($8,190 in cash and 207,375 options), Grignan
Holdings Ltd. ($8,400 in cash), Research Capital
Corp. ($560 in cash and 7,000 options) Bolder
Investment Partners Ltd. ($2,800 in cash and
35,000 options), Canaccord Capital Corp.
($17,276 in cash and 215,950 options) and Besler
Financial Corporations ($700 in cash and 8,750
options) where each option is exercisable into
one common share of the Company at $0.10 per
share for a 24 month period.
Pursuant to Corporate Finance Policy 4.1, Section 1.11(d), the Company
must issue a news release announcing the closing of the private placement and
setting out the expiry dates of the hold period(s). The Company must also
issue a news release if the private placement does not close promptly. Note
that in certain circumstances the Exchange may later extend the expiry date of
the warrants, if they are less than the maximum permitted term.